Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong · Delayed Price · Currency is HKD 5.00
-0.05 (-0.99%)
Aug 11, 2026, 4:08 PM HKT
Sino Biopharmaceutical Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 31,834 | 31,834 | 28,866 | 26,199 | 26,026 | 26,861 |
Revenue Growth | 4.15% | 10.28% | 10.18% | 0.67% | -3.11% | 13.59% |
Gross Profit Gross Profit Growth | 26,127 | 26,127 | 23,530 | 21,210 | 21,539 | 21,529 |
Operating Income Operating Income Growth | 6,291 | 6,291 | 5,801 | 5,439 | 5,386 | 4,633 |
Net Income Net Income Growth | 2,343 | 2,343 | 3,500 | 2,332 | 2,544 | 14,608 |
Earnings Per Share EPS Growth | 0.13 | 0.13 | 0.19 | 0.13 | 0.12 | 0.73 |
EPS Growth | -39.30% | -32.13% | 51.95% | 3.55% | -83.41% | 397.00% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 22,961 | 22,961 | 14,818 | 14,118 | 16,922 | 15,794 |
Total Debt Total Debt Growth | 16,070 | 16,070 | 9,711 | 12,716 | 14,118 | 12,254 |
Net Cash (Debt) Net Cash Growth | 6,891 | 6,891 | 5,107 | 1,402 | 2,804 | 3,540 |
Net Cash Growth | -12.40% | 34.93% | 264.34% | -50.00% | -20.81% | 59.33% |
Net Cash Per Share Net Cash Per Share Growth | 0.38 | 0.38 | 0.28 | 0.08 | 0.15 | 0.18 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 9,292 | 9,292 | 6,615 | 6,066 | 6,265 | 5,366 |
Capital Expenditures CapEx Growth | -1,239 | -1,239 | -960.1 | -1,068 | -1,243 | -1,714 |
Free Cash Flow Free Cash Flow Growth | 8,053 | 8,053 | 5,655 | 4,998 | 5,022 | 3,652 |
Free Cash Flow Growth | 37.10% | 42.41% | 13.15% | -0.48% | 37.50% | -6.38% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 82.07% | 82.07% | 81.51% | 80.95% | 82.76% | 80.15% |
Operating Margin | 19.76% | 19.76% | 20.10% | 20.76% | 20.69% | 17.25% |
Pretax Margin | 21.81% | 21.81% | 18.28% | 20.65% | 20.04% | 69.14% |
Profit Margin | 7.36% | 7.36% | 12.12% | 8.90% | 9.77% | 54.38% |
FCF Margin | 25.30% | 25.30% | 19.59% | 19.08% | 19.30% | 13.60% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.100 | 0.090 | 0.066 | 0.044 | 0.106 | 0.065 |
Dividend Per Share Growth | -44.44% | 36.61% | 48.12% | -58.16% | 62.87% | 5.59% |
Dividend Yield | 1.98% | 1.64% | 2.24% | 1.47% | 2.81% | 1.61% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 34.62 | 42.37 | 15.64 | 24.85 | 29.37 | 5.71 |
Forward PE | 17.81 | 21.62 | 17.48 | 17.77 | 20.63 | 12.33 |
P/FCF Ratio | 9.93 | 12.33 | 9.68 | 11.60 | 14.88 | 22.84 |
PS Ratio | 2.51 | 3.12 | 1.90 | 2.21 | 2.87 | 3.11 |